UCLA Engineers Develop Implantable "Charging Station" to Sustain Immune Cell Attacks on Solid Tumors

UCLA researchers develop a biomimetic "charging station" for CAR-iNKT cells, boosting the durability and effectiveness of immunotherapy against solid tumors.

By: AXL Media

Published: Mar 18, 2026, 9:04 AM EDT

Source: Information for this report was sourced from University of California - Los Angeles

Innovating a Localized Support Hub for Engineered Cancer Immunotherapies

A breakthrough study published in Nature Biomedical Engineering has introduced a specialized implantable platform designed to overcome a primary hurdle in cellular immunotherapy: the rapid loss of immune cell potency. While engineered cells have revolutionized cancer care, they frequently become exhausted or suppressed once they enter the hostile environment of a solid tumor. Researchers at the University of California, Los Angeles, have addressed this by developing a device that functions as a continuous support hub. This system ensures that chimeric antigen receptor-invariant natural killer T cells, known as CAR-iNKT cells, remain in an active state, allowing them to persistently attack cancer cells rather than fading shortly after delivery.

Biomimetic Microparticles Mimicking Natural Immune Activation Signals

The technology relies on tiny engineered microparticles that simulate the natural signals required to activate iNKT cells. According to study co-leader Song Li, a chancellor's professor of bioengineering at UCLA, these particles allow the immune cells to "recharge" and switch back into an aggressive attack mode. By providing sustained molecular cues rather than a single initial boost, the device encourages the cells to multiply and develop long-term memory. This localized approach utilizes TCR antigens to trigger reactivation, paired with capsules that slowly release the signaling protein IL-15, which is essential for the proliferation and survival of the therapeutic cells within the body.

Achieving Systemic Effects Through Targeted Localized Stimulation

Although the device is implanted near a specific tumor site, the resulting immune response is not confined to one area. During laboratory experiments, the UCLA team observed that the recharged CAR-iNKT cells circulated through the bloodstream to seek out and destroy cancer cells throughout the body. This systemic impact is particularly vital for treating metastatic diseases and blood cancers like lymphoma. First author Charlie Li compared the mechanism to a smartphone charging cable, where the physical connection between the immune cell and the TCR antigen initiates a series of molecular signals that propel the cells back into the circulatory system to continue their defensive mission.